158 related articles for article (PubMed ID: 35479283)
21. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
Zhou H; Nie X; Jiang M; Dong W
J Clin Pharm Ther; 2022 Apr; 47(4):523-530. PubMed ID: 34783090
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan.
Liao CT; Lee MC; Chen ZC; Ku LE; Wang JD; Toh HS
Acta Cardiol Sin; 2020 Jan; 36(1):50-61. PubMed ID: 31903008
[TBL] [Abstract][Full Text] [Related]
24. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
25. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
26. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.
Perreault S; Dragomir A; Côté R; Lenglet A; de Denus S; Dorais M; White-Guay B; Brophy J; Schnitzer ME; Dubé MP; Tardif JC
Front Pharmacol; 2021; 12():812018. PubMed ID: 35095525
[No Abstract] [Full Text] [Related]
28. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
Lutsey PL; Norby FL; Ensrud KE; MacLehose RF; Diem SJ; Chen LY; Alonso A
JAMA Intern Med; 2020 Feb; 180(2):245-253. PubMed ID: 31764956
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China.
Wei H; Cui C; Cui X; Liu Y; Li D
BMC Health Serv Res; 2021 Jan; 21(1):96. PubMed ID: 33509171
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation.
Kailas SD; Thambuluru SR
Cureus; 2016 Oct; 8(10):e836. PubMed ID: 27900231
[TBL] [Abstract][Full Text] [Related]
33. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
37. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients.
Hallinen T; Soini EJ; Linna M; Saarni SI
Springerplus; 2016; 5(1):1354. PubMed ID: 27588247
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
